Drug Trial Radar · NCT06033586
Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
Last checked: Nov 20, 2026Latest source record: Aug 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
46
Actual
Start
Jan 22, 2024
Primary completion
Apr 1, 2026
Study completion Apr 1, 2027
Sponsor
- Lead sponsor
- Protagonist Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to assess long-term safety and efficacy of rusfertide in subjects with polycythemia vera. Subjects who complete dosing with rusfertide until the end-of-treatment visit of a Phase 2 rusfertide study and meet the inclusion/exclusion criteria for this study, are eligible to participate in this open-label study and continue treatment with rusfertide.
Conditions
- Polycythemia Vera
Interventions
Open-label rusfertideDrug
subcutaneous rusfertide
Primary outcomes
What the sponsor says the trial is designed to measure.
- HematocritTime frame: 0-2 years
- PhlebotomiesTime frame: 0-2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pontchartrain Cancer Care
Covington, Louisiana
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.